Quince Therapeutics (QNCX) to Release Earnings on Monday

Quince Therapeutics (NASDAQ:QNCX) is expected to release its earnings data before the market opens on Monday, April 7th. Analysts expect Quince Therapeutics to post earnings of ($0.10) per share for the quarter.

Quince Therapeutics (NASDAQ:QNCX) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.09). The business had revenue of $0.17 million for the quarter. On average, analysts expect Quince Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Quince Therapeutics Price Performance

Shares of QNCX opened at $1.24 on Friday. The business’s 50-day moving average is $1.44 and its two-hundred day moving average is $1.47. The company has a market capitalization of $54.56 million, a P/E ratio of -1.00 and a beta of 0.71. Quince Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.45. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53.

Analyst Ratings Changes

Several brokerages recently weighed in on QNCX. D. Boral Capital reduced their price target on Quince Therapeutics from $12.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, March 25th. Oppenheimer began coverage on shares of Quince Therapeutics in a report on Monday, March 24th. They set an “outperform” rating and a $10.00 target price for the company. Finally, Brookline Capital Management began coverage on shares of Quince Therapeutics in a report on Wednesday, December 18th. They set a “buy” rating and a $9.00 price target on the stock. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Quince Therapeutics currently has an average rating of “Buy” and an average target price of $8.00.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.